Cannabix Detects Methamphetamine in Breath, Expanding Drug Testing Potential
Event summary
- Cannabix Technologies detected methamphetamine and amphetamine compounds in human breath samples using its Marijuana Breath Test (MBT) system on July 2, 2026.
- The detection was achieved through the Cannabix Breath Collection Unit (BCU) and analyzed by Omega Laboratories Inc. via liquid chromatography-mass spectrometry (LC-MS).
- Amphetamine-class stimulants are present in breath at extremely low concentrations, making reliable capture technically challenging.
- Cannabix believes this finding supports the potential expansion of its MBT beyond THC detection.
The big picture
Cannabix's ability to detect methamphetamine in breath samples represents a significant validation of its technology, potentially opening new revenue streams beyond cannabis impairment testing. The company is positioning itself as a leader in non-invasive drug screening solutions for workplace safety and law enforcement, addressing critical needs in transportation, construction, and other high-risk industries.
What we're watching
- Market Expansion
- How Cannabix will leverage this detection capability to expand into new markets beyond cannabis testing.
- Technical Validation
- Whether the company can sustain reliable detection of low-concentration stimulants in breath samples.
- Regulatory Approval
- The pace at which Cannabix secures regulatory approvals for expanded drug testing applications.